Nation
World
Politics
Sports
Business
Entertainment
Life
Tech
Science
Opinion
Crime
Health
Oddities

404

Not found

This newslink doesn't exist or it was removed.

Go to Homempage.

Sugerencias de la Hemeroteca

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity

Forbes USA Business October 15, 2022

thumbnailGetty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más

Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business

Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC


Biogen Ends Development of Alzheimer’s Drug Aduhelm

MarketWatch USA Business January 31, 2024

thumbnailThe Aduhelm commercial program had been all but dead since 2022, when the Centers for Medicare & Medicaid Services (CMS) declined to offer Medicare coverage for the drug. Biogen had been continuing of Aduhelm, however, as a condition of the Food and Drug Administration’s... + más

Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes


Biogen Ends Development of Alzheimer’s Drug Aduhelm

MarketWatch USA Business January 31, 2024

thumbnailThe Aduhelm commercial program had been all but dead since 2022, when the Centers for Medicare & Medicaid Services (CMS) declined to offer Medicare coverage for the drug. Biogen had been continuing of Aduhelm, however, as a condition of the Food and Drug Administration’s... + más

Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes


Biogen to cut about 1,000 jobs as it prepares for rollout of Alzheimer’s drug

The Boston Globe USA Business July 25, 2023

thumbnailBiogen said Tuesday that it plans to cut about 1,000 jobs, roughly 11 percent of its global workforce, to lower costs as the Cambridge-based biotech begins to roll out the new Alzheimer’s drug it co-developed and prepares for possible approval of another drug, for depression,... + más

Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes

FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says | Fox Business


Biogen plans to shut down its controversial Alzheimer's drug Aduhelm

WPLG Local 10 USA Health January 31, 2024

thumbnailBiogen will stop developing its Alzheimer’s treatment , a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.The drugmaker said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug... + más

Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch

Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch



About iurex | Privacy Policy | Disclaimer |